---
title: "Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: TYK2 inhibitors"
description: "Formulary evidence on Envudeucitinib (ESK-001, FTP-637) in Moderate-to-severe plaque psoriasis: TYK2 inhibitors. Topics: FDA-approved indication, dosage, and pretreatment tuberculosis evaluation: deucravacitinib; Trial PSO-1 efficacy versus placebo and apremilast: deucravacitinib label; POETYK PSO-1: week 16 PASI 75 and sPGA 0/1 versus placebo and apremilast; POETYK PSO-2: week 16 PASI 75 and sPGA 0/1 versus placebo and apremilast; 11 further topics. 15 evidence topics quoted from 11 sources."
canonical: "https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description/tyk2-inhibitors"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: TYK2 inhibitors

<a id="heading-2.2.2.1.5"></a>

## 2.2.2.1.5 TYK2 Inhibitors

<a id="topic-2.2.2.1.5-1"></a>

### FDA-approved indication, dosage, and pretreatment tuberculosis evaluation: deucravacitinib

> “SOTYKTU is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.”
> “The recommended dosage of SOTYKTU is 6 mg taken orally once daily, with or without food.”
> “Evaluate patients for active and latent tuberculosis (TB) infection prior to initiating treatment with SOTYKTU.”

Source: [Bristol Myers Squibb SOTYKTU prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/214958s006sdn685lbl.pdf)

<a id="topic-2.2.2.1.5-2"></a>

### Trial PSO-1 efficacy versus placebo and apremilast: deucravacitinib label

| Endpoint, n (%) | SOTYKTU (N=330) | Placebo (N=166) | Apremilast (N=168) |
| --- | --- | --- | --- |
| sPGA 0/1, Week 16 | “178 (54)” | “12 (7)” | “54 (32)” |
| PASI 75, Week 16 | “193 (58)” | “21 (13)” | “59 (35)” |
| PASI 90, Week 16 | “118 (36)” | “7 (4)” | “33 (20)” |

Source: [Bristol Myers Squibb SOTYKTU prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/214958s006sdn685lbl.pdf)

| Endpoint at Week 24, Trial PSO-1, n (%) | SOTYKTU (N=330) | Apremilast (N=168) |
| --- | --- | --- |
| PASI 75 | “228 (69)” | “64 (38)” |
| PASI 90 | “140 (42)” | “37 (22)” |

Source: [Bristol Myers Squibb SOTYKTU prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/214958s006sdn685lbl.pdf)

<a id="topic-2.2.2.1.5-3"></a>

### POETYK PSO-1: week 16 PASI 75 and sPGA 0/1 versus placebo and apremilast

> “Participants were randomized 2:1:1 to deucravacitinib 6 mg every day (n = 332), placebo (n = 166), or apremilast 30 mg twice a day (n = 168) in the 52-week, double-blinded, phase 3 POETYK PSO-1 trial (NCT03624127).”
> “At week 16, response rates were significantly higher with deucravacitinib versus placebo or apremilast for PASI 75 (194 [58.4%] vs 21 [12.7%] vs 59 [35.1%]; P < .0001) and sPGA 0/1 (178 [53.6%] vs 12 [7.2%] vs 54 [32.1%]; P < .0001).”
> “Adverse event rates with deucravacitinib were similar to those with placebo and apremilast.”

Source: [Armstrong et al. (2023a)](https://pubmed.ncbi.nlm.nih.gov/35820547/)

<a id="topic-2.2.2.1.5-4"></a>

### POETYK PSO-2: week 16 PASI 75 and sPGA 0/1 versus placebo and apremilast

> “POETYK psoriasis second trial (NCT03611751), a 52-week, double-blinded, phase 3 trial, randomized patients 2:1:1 to deucravacitinib 6 mg every day (n = 511), placebo (n = 255), or apremilast 30 mg twice a day (n = 254).”
> “At week 16, significantly more deucravacitinib-treated patients versus placebo and apremilast patients achieved ≥75% reduction from baseline in Psoriasis Area and Severity Index (53.0% vs 9.4% and 39.8%; P < .0001 vs placebo; P = .0004 vs apremilast) and static Physician's Global Assessment score of 0 or 1 (49.5% vs 8.6% and 33.9%; P < .0001 for both).”
> “The most frequent adverse event with deucravacitinib was nasopharyngitis.”
> “Serious adverse events and discontinuations due to adverse events were infrequent.”

Source: [Strober et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36115523/)

<a id="topic-2.2.2.1.5-5"></a>

### Randomized withdrawal: maintenance of sPGA 0 or 1 at week 52 with continued deucravacitinib versus placebo

> “For subjects who were re-randomized and also had a sPGA score of 0 or 1 at Week 24, 70% (83/118) of subjects who continued on SOTYKTU maintained this response (sPGA 0 or 1) at Week 52 compared to 24% (28/119) of subjects who were re-randomized to placebo.”

Source: [Bristol Myers Squibb SOTYKTU prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/214958s006sdn685lbl.pdf)

<a id="topic-2.2.2.1.5-6"></a>

### Adverse reactions through week 16 in Trials PSO-1 and PSO-2: deucravacitinib label

| Adverse reaction, n (%) | SOTYKTU 6 mg once daily (N=840) | Placebo (N=419) |
| --- | --- | --- |
| Upper respiratory infections | “161 (19.2)” | “62 (14.8)” |
| Blood creatine phosphokinase increased | “23 (2.7)” | “5 (1.2)” |
| Herpes simplex | “17 (2)” | “1 (0.2)” |
| Mouth ulcers | “16 (1.9)” | “0 (0.0)” |
| Folliculitis | “14 (1.7)” | “0 (0.0)” |

Source: [Bristol Myers Squibb SOTYKTU prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/214958s006sdn685lbl.pdf)

<a id="topic-2.2.2.1.5-7"></a>

### Warnings: infections, creatine phosphokinase elevation, triglycerides, and potential JAK inhibition risks

> “In the 16-week placebo-controlled period of the pooled clinical trials (Trials PSO-1 and PSO-2), discontinuation of therapy due to adverse reactions in subjects who received SOTYKTU was 2.4%, compared to 3.8% for placebo.”
> “SOTYKTU may increase the risk of infections.”
> “The most common serious infections reported with SOTYKTU included pneumonia and COVID-19”
> “Treatment with SOTYKTU was associated with an increased incidence of asymptomatic creatine phosphokinase (CPK) elevation and rhabdomyolysis compared to treatment with placebo.”
> “Triglyceride Elevations - Treatment with SOTYKTU was associated with increases in triglyceride levels”
> “It is not known whether TYK2 inhibition may be associated with the observed or potential adverse reactions of Janus Kinase (JAK) inhibition.”

Source: [Bristol Myers Squibb SOTYKTU prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/214958s006sdn685lbl.pdf)

<a id="topic-2.2.2.1.5-8"></a>

### Continuous deucravacitinib: PASI 90 and DLQI 0/1 through 4 years

> “In patients who received continuous deucravacitinib (n = 513), clinical and patient‐reported outcome rates were well maintained from 1 year through 4 years (e.g. PASI 90, 1 year, 45.6% [95% CI, 41.3%–50.0%], 4 years, 47.5% [42.6%–52.4%]; DLQI 0/1, 1 year, 51.5% [47.1%–55.9%], 4 years, 49.4% [44.4%–54.4%]).”

Source: [Armstrong et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12188513/)

<a id="topic-2.2.2.1.5-9"></a>

### Deucravacitinib exposure-adjusted safety through 5 years

> “Overall, 1519 patients received one or more deucravacitinib dose; total exposure was 5046.7 PY through data cutoff (September 2, 2024).”
> “EAIRs/100 PY were comparable or decreased from the 1-year to 5-year cumulative period for adverse events (AEs) (229.23, 127.40, respectively), serious AEs (5.68, 5.06), discontinuation due to AEs (4.38, 2.09), deaths (0.20, 0.22), serious infections excluding coronavirus disease 2019 (COVID-19) (1.53, 0.94), malignancies (1.02, 0.92), major adverse cardiovascular events (0.30, 0.34), and venous thromboembolism (0.20, 0.06).”

Source: [Armstrong et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13578007/)

<a id="topic-2.2.2.1.5-10"></a>

### Guideline statements: deucravacitinib infections, herpes zoster, laboratory changes, and malignancies

> “Deucravacitinib may increase the risk of infection.”
> “During the pivotal trials POETYK PSO‐1, PSO‐2 and the open‐label extension study, ten of the 18 patients reporting herpes zoster were less than 50 years old.”
> “Pooled data from clinical trials on changes in laboratory findings show that treatment with deucravacitinib may result in the following changes in laboratory findings: increase of creatine kinase (from asymptomatic to rhabdomyolysis), increase of triglyceride levels and increase of liver enzymes by ≥ 3‐fold of the upper limit of normal.”
> “In the pooled data from the complete treatment periods of the pivotal trials PSO‐1, PSO‐2, and the open‐label extension study (overall, 2,482 patient‐years of exposure with deucravacitinib), malignancies were reported in 22 patients (0.9 per 100 patient‐years), including eleven cases of non‐melanoma skin cancer (0.4 per 100 patient‐years) and three cases of lymphoma (0.1 per 100 patient‐years).”

Source: [Nast et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12800871/)

<a id="topic-2.2.2.1.5-11"></a>

### Network meta-analysis: deucravacitinib compared with biologics and apremilast for PASI 90

> “There was evidence of a difference in favour of infliximab, anti‐IL17 agents (bimekizumab, ixekizumab, secukinumab, sonelokimab, brodalumab), and anti‐IL23 agents (risankizumab and guselkumab) compared to ustekinumab, tildrakizumab, the three anti‐TNF‐alpha agents (adalimumab, certolizumab, and etanercept), and deucravacitinib in terms of achieving PASI 90.”
> “Deucravacitinib and risankizumab were more effective than apremilast.”

Source: [Sbidian et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12327466/)

<a id="topic-2.2.2.1.5-12"></a>

### Zasocitinib: phase 2b dose-ranging trial, PASI 75 at week 12

> “Patients were randomly assigned (1:1:1:1:1) to receive zasocitinib at 2, 5, 15, or 30 mg or placebo orally, once daily, for 12 weeks.”
> “At week 12, PASI 75 was achieved for 9 (18%), 23 (44%), 36 (68%), and 35 (67%) patients receiving zasocitinib at 2, 5, 15, and 30 mg, respectively, and 3 patients (6%) receiving placebo.”
> “Treatment-emergent adverse events occurred for 23 patients (44%) receiving placebo and 28 (53%) to 31 (62%) patients receiving the 4 different doses of zasocitinib, with no dose dependency and no clinically meaningful longitudinal differences in laboratory parameters.”

Source: [Armstrong et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11339701/)

<a id="topic-2.2.2.1.5-13"></a>

### Zasocitinib: LATITUDE PsO 3001 and 3002 week 16 results versus placebo and apremilast

| Endpoint at Week 16 | LATITUDE PsO 3001 | LATITUDE PsO 3002 |
| --- | --- | --- |
| sPGA 0/1 | “71% zasocitinib vs 11% placebo and 32% apremilast (p<0.001)” | “69% zasocitinib vs 13% placebo and 30% apremilast (p<0.001)” |
| PASI 75 | “76% zasocitinib vs 12% placebo and 37% apremilast (p<0.001)” | “71% zasocitinib vs 12% placebo and 33% apremilast (p<0.001)” |

Source: [Takeda press release, zasocitinib NDA acceptance (2026)](https://www.takeda.com/newsroom/newsreleases/2026/fda-priority-review-zasocitinib-psoriasis/)

> “The studies were conducted in 21 countries and enrolled 693 and 1,108 participants, respectively.”
> “Scalp: 77% and 74% of patients with scalp psoriasis treated with zasocitinib achieved scalp-specific PGA (ssPGA) 0/1 response versus placebo (7% and 13%; p<0.001) and apremilast (42% and 30%; p<0.001) at week 16.”

Source: [Takeda press release, zasocitinib skin clearance across body sites (2026)](https://www.takeda.com/newsroom/newsreleases/2026/zasocitinib-phase-3-psoriasis-skin-clearance/)

<a id="topic-2.2.2.1.5-14"></a>

### Zasocitinib versus deucravacitinib: LATITUDE Atlas week 16 results

> “In the Phase 3 LATITUDE Atlas (TAK-279 PsO 3004) head-to-head study, zasocitinib demonstrated statistical superiority over deucravacitinib across the primary and all key secondary efficacy endpoints with higher rates of complete skin clearance observed as early as week 8 and more than 2.5 times as many patients achieving complete skin clearance at week 16.”
> “36.5% of patients treated with zasocitinib (n=301) achieved complete skin clearance (Psoriasis Area and Severity Index (PASI) 100) at week 16 versus 13.9% in the deucravacitinib group (n=303; p<0.001).”
> “62.5% of patients treated with zasocitinib achieved PASI 90 at week 16 versus 34.0% in the deucravacitinib group (p<0.001).”
> “43.2% of patients treated with zasocitinib achieved clear skin (static Physician Global Assessment (sPGA) 0) at week 16 versus 18.5% in the deucravacitinib group (p<0.001).”
> “The most common adverse events across Phase 3 LATITUDE psoriasis trials were upper respiratory tract infection, nasopharyngitis and acne.”

Source: [Takeda press release, LATITUDE Atlas results (2026)](https://www.takeda.com/newsroom/newsreleases/2026/zasocitinib-superior-efficacy/)

<a id="topic-2.2.2.1.5-15"></a>

### Zasocitinib: NDA accepted under Priority Review, PDUFA target in the first quarter of 2027

> “Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) under Priority Review for zasocitinib (TAK-279) for the treatment of adults with moderate-to-severe plaque psoriasis.”
> “The Prescription Drug User Fee Act (PDUFA) target action date is in the first quarter of calendar year 2027”

Source: [Takeda press release, zasocitinib NDA acceptance (2026)](https://www.takeda.com/newsroom/newsreleases/2026/fda-priority-review-zasocitinib-psoriasis/)

## Related pages
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Terms and abbreviations](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations.md)
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Product information and disease description](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Clinical evidence](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Economic information and modeling report](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: References](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references.md)
